Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Enfuvirtide.

Toni M Dando1, Caroline M Perry

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Drugs
|December 11, 2003
PubMed
Summary
This summary is machine-generated.

Enfuvirtide, a fusion inhibitor, effectively reduces HIV RNA and increases CD4+ cells in adults and children. While generally safe, local injection-site reactions and increased risks of lymphadenopathy and pneumonia were observed.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Aripiprazole (ABILIFY MAINTENA®): a review of its use as maintenance treatment for adult patients with schizophrenia.

Drugs·2014
Same author

Sevelamer carbonate: a review in hyperphosphataemia in adults with chronic kidney disease.

Drugs·2014
Same author

Rivaroxaban: a review of its use in the treatment of deep vein thrombosis or pulmonary embolism and the prevention of recurrent venous thromboembolism.

Drugs·2014
Same author

Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Stribild®): a review of its use in the management of HIV-1 infection in adults.

Drugs·2013
Same author

Simeprevir: first global approval.

Drugs·2013
Same author

Raltegravir: a review of its use in the management of HIV-1 infection in children and adolescents.

Paediatric drugs·2013
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Virology
  • Immunology
  • Pharmacology

Background:

  • Enfuvirtide is a novel fusion inhibitor targeting HIV glycoprotein 41 (gp41).
  • Resistance to enfuvirtide has emerged in patients on combination therapy.
  • Understanding its efficacy and safety in diverse patient populations is crucial.

Purpose of the Study:

  • To evaluate the efficacy and safety of enfuvirtide in combination with optimized background therapy.
  • To assess the impact of enfuvirtide on viral load and CD4+ cell counts.
  • To investigate enfuvirtide's effects in both adult and pediatric HIV patients.

Main Methods:

  • Two randomized trials in adults with advanced HIV infection.
  • Combination therapy with enfuvirtide (90mg subcutaneously twice daily) and optimized background (OB) therapy.

Related Experiment Videos

  • A smaller trial assessing enfuvirtide (30 or 60 mg/m(2)) in pediatric patients.

    • Main Results:

    • Significant reduction in plasma HIV RNA levels compared to OB alone at 24 and 48 weeks.
    • Greater increase in CD4+ cell counts from baseline in the enfuvirtide plus OB group.
    • Antiviral efficacy was maintained up to 48 weeks in adults.
    • Reduced HIV RNA and increased CD4+ cells observed in pediatric patients.

    Conclusions:

    • Enfuvirtide is an effective antiviral agent for adults and children with HIV when used with optimized background therapy.
    • The drug demonstrates sustained efficacy and improves immune status.
    • Common adverse events include injection-site reactions; increased incidence of lymphadenopathy and pneumonia noted.